Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-5 of 5
Keywords: Interferon-α
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1996) 19 (3): 214–219.
Published Online: 12 May 2009
... with metastatic disease (palliative) surgery may be indicated, too. (Chemo-) Embolization should to be considered for liver metastases causing severe local symptoms. Recently, biotherapy with somatostatins or interferon-α has revolutionized the treatment of metastatic neuroendocrine tumor disease...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1996) 19 (3): 226–230.
Published Online: 12 May 2009
...-IIa we suggest PUVA alone or in combination with retinoids as the first-line therapy. If there is disease progression, interferon-α or methotrexate shall be added. CTCL cases in stage lib can be treated with PUVA combined with interferon-α and soft X-ray radiation (6-8 ×200 cGy, 50 kV twice/week...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1994) 17 (3): 263–269.
Published Online: 11 May 2009
...I. Funke; E. Späth-Schwalbe; G. Stohlmann; O. Prümmer; H. Gallati; H. Schrezenmeier; F. Porzsolt Background: In advanced renal cell cancer (RCC) interleukin-2 (IL-2) and interferon-α (IFN-α) have shown modest clinical activity as single agents, substantial toxicity being associated with IL-2...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1991) 14 (2): 178–180.
Published Online: 28 April 2009
...H. Hausmaninger; B. Oentrich; K. Nachbaur; D. Niederwieser; R. Haidinger; C. Huber Im Rahmen einer Phase-2-Studie wird versucht, eine Ansprechrate von 60–80%, die bei Patienten mit metastasierenden gastrointestinalen Karzinomen mit der Kombination 5-Fluorouracil und Interferon-α erreicht wurde, zu...
Journal Articles
Subject Area:
Oncology
H. Ludwig, W. Scheithauer, I. Kührer, R. Kuzmits, G. Gisslinger, W. Linkesch, Ch. Zielinski, E. Fritz
Journal:
Onkologie
Onkologie (1988) 11 (4): 192–196.
Published Online: 27 April 2009
...H. Ludwig; W. Scheithauer; I. Kührer; R. Kuzmits; G. Gisslinger; W. Linkesch; Ch. Zielinski; E. Fritz Natürliches Leukozyteninterferon und rekombinantes Interferon-α-2 bewirken beim multiplen Myelom Remissionsraten zwischen 10 und 20%, wobei nicht chemotherapeutisch vorbehandelte Patienten höhere...